
What smart money is saying about ROVI
1 fund in our archive has pitched ROVI, most recently Glendale Equity in September 2026.
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
Get an email when a fund buys, sells or pitches it
Position history
Between Q2 2026 and Q3 2026, 2 fund letters reported a position in ROVI, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 1 |
| Q2 2026 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions
- HoldsGlendale EquitySeptember 2026
“The situation is different at ROVI, where we still expect a fundamental part of our thesis to materialize.”
ROVI - HoldsDNCA Invest Explorer Smid EuroJune 2026
“Conversely, Laboratorios Farmaceuticos Rovi, a pharmaceutical company, lowered its annual outlook due to delays in the start of production for one of its main clients in pharmaceutical subcontracting activities.”
ROVI
Fund coverage · 1 thesis
- Glendale EquitySeptember 2026
ROVI is adding CDMO capacity and staff ahead of the volumes that should make those investments profitable, and the expected operating leverage depends on signing new manufacturing contracts with pharmaceutical companies.
Read the full thesis
Read every full thesis on ROVI
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→